"These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project. " - p. iv

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.

The Federal Guidelines for Opioid Treatment Programs (Guidelines) describe the Substance Abuse and Mental Health Services Administration's (SAMHSA) expectation of how the federal opioid treatment standards found in Title 42 of the Code of Federal Regulations Part 8 (42 CFR � 8) are to be satisfied by opioid treatment programs (OTPs). Under these federal regulations, OTPs are required to have current valid accreditation status, SAMHSA certification, and Drug Enforcement Administration (DEA) registration before they are able to administer or dispense opioid drugs for the treatment of opioid addiction.

This guide is for physicians and medical professionals using medicated-assisted treatment for patients with opioid use disorder. It discusses various types of approved medications, screening and assessment tools, and best practices for patient care. Included is a checklist plus several tables addressing numerous areas including frequency of administration, ideal candidates for clinical uses, pregnant and postpartum women use, clinical opiate withdrawal scale, and more.

This book addresses opioids and opioid use disorders from epidemiological, clinical, and public health perspectives. It covers detailed information on the nature of opioids, their effects on the human body and brain, prevention, and treatment of opioid addiction. Unlike other texts, the first section of this volume builds a strong historical, neurobiological, and phenomenological foundation for a deep understanding of the topic and the patient. The second section addresses the most challenging issues clinicians face, including pharmacological and psychosocial treatments, harm reduction approaches, alternative approaches to pain management for the non-specialist, and prescribing guidelines. Treating Opioid Addiction is a valuable resource for psychiatrists, psychologists, addiction medicine physicians, primary care physicians, drug addiction counselors, students, trainees, scholars, and public health officials interested in the effects and impact of opioids in the clinical and epidemiological context.

Gain guidance and support when treating the high-risk population of women confronting (or battling) opioid-use disorders during pregnancy.

Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.

The American Society of Addiction Medicine Handbook on Pain and Addiction provides clinical considerations and guidelines for the clinician treating patients with pain and addiction. Produced by the largest medical society dedicated to the improvement of addiction care, the book takes an evidence-based approach and uses articles from both the literature and well-regarded organizations and government agencies including NIDA, CDC, SAMHSA, PCSS-O, and ASAM itself. The ASAM Handbook is structured in five sections that cover the core concepts of addressing pain and addiction; diagnosis and treatment; treating pain in patients with, or at risk for, co-occuring addiction; treating substance use disorders (SUD) and addiction in patients with co-occuring pain; and adapting treatment to the needs of specific populations. Each chapter ends with suggestions for further reading on the topics discussed. This book is ideal for primary care providers, mental health clinicians, SUD clinicians, and pain clinicians who wish to bridge the knowledge gaps related to treating patients with pain and addiction. To learn more about the American Society of Addiction Medicine, and its commitment to providing the best resources for addiction clinicians, please visit http://www.asam.org.

This guide is intended to provide nurses (including Registered Nurses, Licensed Practical Nurses, and Nurse Practitioners) with general info. about buprenorphine products ¿ Suboxone® (buprenorphine and naloxone) and Subutex® (buprenorphine) ¿ for the pharmacological treatment of opioid addiction. The guide can also serve as a resource to help nurses working with community physicians to improve treatment outcomes for individuals receiving office-based treatment for opioid addiction. Nurses in all settings may be called upon to work with individuals undergoing treatment for opioid addiction with buprenorphine products and with physicians to improve treatment outcomes by providing behavioral treatment and counseling. Illustrations.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat opioid use disorder (OUD)—methadone, naltrexone, and buprenorphine—and provides guidance for healthcare professionals and addiction treatment providers on appropriate prescribing practices for these medications and effective strategies for supporting the patients utilizing medication for the treatment of OUD. The goal of treatment for opioid addiction or OUD is remission of the disorder leading to lasting recovery. Recovery is a process of change through which individuals improve their health and wellness, live self-directed lives, and strive to reach their full potential. This TIP also educates patients, families, and the general public about how OUD medications work and the benefits they offer. Related products: Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide A Shared Burden: The Military and Civilian Consequences of Army Pain Management Since 2001 Click our Alcoholism, Smoking & Substance Abuse collection to find more resources on this topic.